Competing trials are under way that may show that the benefits of SGLT2 inhibitors in heart failure are a class effect. Sodium glucose cotransporter 2 (SGLT2) inhibitors, first approved to treat type ...
Objectives: The efficacy of dapagliflozin as add-on therapy to metformin has been assessed in randomized trials. However, its effectiveness has not been assessed in a US real-world setting. Methods: ...
Dapagliflozin improved eGFR slope in patients with CKD associated with ADPKD, but it resulted in an increase in kidney volume. Dapagliflozin may exert a protective effect on kidney function in ...
Bristol-Myers Squibb and AstraZeneca announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin demonstrated significant reductions in HbA1C compared with ...
PHILADELPHIA, PA—Dapagliflozin (Farxiga; AstraZeneca), originally developed for the treatment of type 2 diabetes, has a broad, positive impact across various subsets of patients with chronic heart ...
Regardless of diabetes status, patients with chronic kidney disease (CKD) have better renal and cardiovascular outcomes as well as a lower chance of dying when dapagliflozin (Farxiga; AstraZeneca) is ...
Amit Bansal, Managing Director, Theon Pharmaceuticals Ltd says this fixed-dose combination tablet of linagliptin, dapagliflozin, and metformin hydrochloride is a suitable option for the following ...
In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms.
Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...
Please provide your email address to receive an email when new articles are posted on . A combination of the glucagon-like peptide-1 receptor agonist exenatide and the SGLT2 inhibitor dapagliflozin is ...
Please provide your email address to receive an email when new articles are posted on . Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent ...
Glycemic control for many patients with type 2 diabetes mellitus (T2DM) is elusive, and the adverse effects of treatment, including hypoglycemia and weight gain, are partially culpable. Until recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback